Table 2.
Clinical characteristics of the infected and noninfected patients
| Characteristics | Confirmed diagnosis | Clinically diagnosed | Noninfected |
|---|---|---|---|
| No. of patients | 15 | 27 | 188 |
| Sex, n (%) | |||
| Male | 10 (67) | 15 (56) | 107 (57) |
| Female | 5 (33) | 12 (44) | 81 (42) |
| Age, years | |||
| Median (IQR) | 71 (54–76) | 61 (47–68) | 58 (22–91) |
| HD age, mo | |||
| Median (IQR) | 32 (14–43) | 35 (16–61) | 47 (2–261) |
| Albumin, g/l | |||
| Median (IQR) | 39 (36–44) | 40 (35–46) | 40 (15–56) |
| Hemoglobin, g/l | |||
| Median (IQR) | 124 (100–152) | 112 (103–141) | 110 (93–118) |
| Kt/V | |||
| Median (IQR) | 1.19 (1.15–1.45) | 1.33 (1.17–1.56) | 1.36 (1.05–1.42) |
| iPTH, pg/ml | |||
| Median (IQR) | 400 (196–555) | 248 (86–329) | 356 (169–684) |
| Primary cause of end-stage renal disease, n (%) | |||
| Glomerulonephritis | 8 (53) | 15 (55) | 52 (31) |
| Hypertensive nephropathy | 5 (33) | 8 (30) | 46 (27) |
| Diabetic nephropathy | 1 (7) | 4 (15) | 11(7) |
| Polycystic kidney disease | 1 (7) | 0 | 3 (2) |
| Access, n (%) | |||
| CVC | 6 (40) | 8 (28) | 39 (21) |
| AVF | 9 (60) | 19 (72) | 147 (78) |
| Artificial blood vessel | 0 | 0 | 2 (1) |
AVF, arteriovenous fistula; CVC, central venous catheter; iPTH, intact parathyroid hormone; IQR, interquartile range.